Perfusion system and a method for the large scale production of virus or
virus antigen
    1.
    发明授权
    Perfusion system and a method for the large scale production of virus or virus antigen 失效
    灌注系统和大规模生产病毒或病毒抗原的方法

    公开(公告)号:US5719051A

    公开(公告)日:1998-02-17

    申请号:US357292

    申请日:1994-12-13

    IPC分类号: A61K39/12 C12N7/02 C12N7/01

    摘要: The invention resides in a matrix, i.e. in a carrier material, with human or animal cells adherently bound thereto, the cells being infected with virus. It has shown that surface-dependent cells suitable for virus propagation remain adherently bound to a matrix even in the virus-infected state, continuously produce virus antigen over relatively long periods of time and deliver them into the culture medium. For producing TBE virus antigen by growing tick-borne encephalitis (TBE) virus in cell cultures, a surface-dependent permanent cell line, preferably the Vero cell line ATCC CCL 81, is inoculated with TBE virus, and the cells are kept bound to carriers in a non-lyric serum-free system while maintaining the cell growth, so as to maintain antigen formation, whereupon the antigen-containing medium is separated form the carrier-bound cells and, in a known manner, is processed to a galencially acceptable preparation by concentration, inactivation and purification.

    摘要翻译: 本发明涉及一种基质,即在载体材料中,与人或动物细胞贴壁结合,细胞被病毒感染。 已经表明,即使在病毒感染状态下,适用于病毒传播的表面依赖性细胞仍保持与基质结合,在相对长的时间内连续产生病毒抗原并将其输送到培养基中。 为了通过在细胞培养物中生长蜱传导性脑炎(TBE)病毒来生产TBE病毒抗原,表面依赖的永久性细胞系(优选Vero细胞系ATCC CCL 81)用TBE病毒接种,并且细胞保持与载体结合 在保持细胞生长的同时,在非抒情的无血清系统中,从而保持抗原形成,由此将含抗原的培养基从载体结合的细胞分离,并以已知的方式加工成半衰期可接受的制剂 通过浓缩,灭活和纯化。

    Method for virus inactivation in the presence of polyalkylene glycol as
well as the pharmaceutical preparation obtained therewith
    9.
    发明授权
    Method for virus inactivation in the presence of polyalkylene glycol as well as the pharmaceutical preparation obtained therewith 失效
    在聚亚烷基二醇存在下进行病毒灭活的方法以及由其获得的药物制剂

    公开(公告)号:US5770199A

    公开(公告)日:1998-06-23

    申请号:US624516

    申请日:1996-06-28

    摘要: The invention relates to a pharmaceutical preparation comprising a plasma protein wherein said preparation is free of infectious agents as well as essentially free of denaturation products and is obtainable by a method that encompasses the following steps: a) addition of a polyether and a chaotropic agent to a solution comprising the plasma protein, optional lyophilization of the solution; b) inactivation of infectious agents in the presence of the polyether by a physio-chemical or chemical treatment, and c) removal of the polyether and the chaotropic agent.

    摘要翻译: PCT No.PCT / IB95 / 00019 Sec。 371日期:1996年6月28日 102(e)日期1996年6月28日PCT提交1995年1月10日PCT公布。 公开号WO95 / 09657 日期1995年4月13日本发明涉及包含血浆蛋白质的药物制剂,其中所述制剂不含感染因子,基本上不含变性产物,并且可通过包括以下步骤的方法获得:a)加入聚醚 以及将离液剂加入到包含血浆蛋白质的溶液中,任选地冻干溶液; b)通过物理化学或化学处理在聚醚存在下使感染剂失活,以及c)除去聚醚和离液剂。